PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$145.16
+0.05%Price chart
Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10
ValuationView details →
P/E (Fwd)
72.5x
EV/EBITDA
100.8x
Market Cap
$9.39B
MomentumView details →
1D Return
+0.05%
YTD Return
+66.43%
RSI (14)
48.8
ValuationView details →
P/E (Fwd)
72.5x
EV/EBITDA
100.8x
Market Cap
$9.39B
RSI (14)
48.8
MomentumView details →
1D Return
+0.05%
YTD Return
+66.43%
SummaryUpdated Jun 1, 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.
Similar companies
Latest newsMore news →
Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.2d agoThe U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.13d ago